One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin

Daniel B. Brown; Carin F. Gonsalves; Charles J. Yeo; Agnes K. Witkiewicz; Brian I. Carr

doi:10.3892/or_00000919

One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin

Daniel B. Brown, Carin F. Gonsalves, Charles J. Yeo, Agnes K. Witkiewicz, Brian I. Carr

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.

Original language	English (US)
Pages (from-to)	767-769
Number of pages	3
Journal	Oncology reports
Volume	24
Issue number	3
DOIs	https://doi.org/10.3892/or_00000919
State	Published - Sep 2010

Keywords

Chemoembolization
Gemcitabine
Pancreatic carcinoma

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3892/or_00000919

Cite this

@article{2bbce7c5b0514140b5970325b1e5ecaa,

title = "One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin",

abstract = "While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.",

keywords = "Chemoembolization, Gemcitabine, Pancreatic carcinoma",

author = "Brown, {Daniel B.} and Gonsalves, {Carin F.} and Yeo, {Charles J.} and Witkiewicz, {Agnes K.} and Carr, {Brian I.}",

year = "2010",

month = sep,

doi = "10.3892/or_00000919",

language = "English (US)",

volume = "24",

pages = "767--769",

journal = "Oncology reports",

issn = "1021-335X",

publisher = "Spandidos Publications",

number = "3",

}

TY - JOUR

T1 - One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin

AU - Brown, Daniel B.

AU - Gonsalves, Carin F.

AU - Yeo, Charles J.

AU - Witkiewicz, Agnes K.

AU - Carr, Brian I.

PY - 2010/9

Y1 - 2010/9

N2 - While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.

AB - While hepatic arterial chemoembolization is efficacious for a number of malignancies, there is scant data regarding treatment of pancreatic adenocarcinoma. We report a complete radiographic response at one year from diagnosis of metastatic pancreatic carcinoma. Gemcitabine/cisplatin based chemoembolization may be of potential benefit for patients with liver-dominant metastases from pancreatic carcinoma. Given the typical survival of 6 months or less in this patient group with standard therapies, further research is warranted.

KW - Chemoembolization

KW - Gemcitabine

KW - Pancreatic carcinoma

UR - http://www.scopus.com/inward/record.url?scp=77956325761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956325761&partnerID=8YFLogxK

U2 - 10.3892/or_00000919

DO - 10.3892/or_00000919

M3 - Article

C2 - 20664985

AN - SCOPUS:77956325761

SN - 1021-335X

VL - 24

SP - 767

EP - 769

JO - Oncology reports

JF - Oncology reports

IS - 3

ER -

One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this